ATSN-101 is under clinical development by Atsena Therapeutics and currently in Phase II for Leber Congenital Amaurosis (LCA). According to GlobalData, Phase II drugs for Leber Congenital Amaurosis (LCA) have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ATSN-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ATSN-101 overview

ATSN-101 is under development for the treatment of leber congenital amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations. It comprises adeno-associated virus serotype 5 (AAV5) encoding human retinal guanylate cyclase 1 gene. The therapeutic candidate is administered through intraocular route in the form of solution. It is a subretinal gene therapy product being developed using adeno-associated virus (AAV) technologies.

Atsena Therapeutics overview

Atsena Therapeutics is an US based clinical-stage gene therapy company. The company is evaluating a gene therapy for patients with GUCY2D-associated leber congenital amaurosis (LCA1) to prevent blindness for children.

For a complete picture of ATSN-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.